D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 52 Citations 16,908 126 World Ranking 2530 National Ranking 1212

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Immune system

His primary scientific interests are in Antigen, Immunology, T cell, Immunotherapy and Chimeric antigen receptor. His Antigen research includes themes of Cytotoxic T cell and Adoptive cell transfer. His study focuses on the intersection of Immunology and fields such as Transplantation with connections in the field of Chronic myelogenous leukemia.

His T cell study integrates concerns from other disciplines, such as Graft-versus-host disease, Ex vivo, Protein kinase A and B cell. The study incorporates disciplines such as Pathology, Antibody, In vivo and Monoclonal in addition to Immunotherapy. His work deals with themes such as Cancer research and Prostate cancer, which intersect with Chimeric antigen receptor.

His most cited work include:

  • Chimeric antigen receptor T cells for sustained remissions in leukemia. (2837 citations)
  • Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (917 citations)
  • Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas (679 citations)

What are the main themes of his work throughout his whole career to date?

J. Joseph Melenhorst mainly focuses on Immunology, T cell, Chimeric antigen receptor, CD8 and Antigen. His Immunology research is multidisciplinary, incorporating elements of Internal medicine and Stem cell. His work carried out in the field of T cell brings together such families of science as Cytotoxic T cell, Lymphocyte, Oncology and B cell.

His Chimeric antigen receptor research incorporates themes from Cancer research, Cell therapy and CD19. The CD8 study combines topics in areas such as T lymphocyte, Molecular biology, Human leukocyte antigen, T-cell receptor and Transplantation. In his research on the topic of Antigen, Chronic lymphocytic leukemia is strongly related with Antibody.

He most often published in these fields:

  • Immunology (67.16%)
  • T cell (44.12%)
  • Chimeric antigen receptor (26.96%)

What were the highlights of his more recent work (between 2016-2021)?

  • Chimeric antigen receptor (26.96%)
  • Immunotherapy (13.73%)
  • Cancer research (23.53%)

In recent papers he was focusing on the following fields of study:

J. Joseph Melenhorst spends much of his time researching Chimeric antigen receptor, Immunotherapy, Cancer research, T cell and Antigen. His Chimeric antigen receptor research is multidisciplinary, relying on both B cell, Adoptive cell transfer, CD19 and Lymphoma. Immunotherapy is a subfield of Immunology that J. Joseph Melenhorst investigates.

His research in Cancer research intersects with topics in Mesothelin, Cancer, Cell, Cell therapy and Immune system. His T cell study combines topics from a wide range of disciplines, such as Oncology, Diffuse large B-cell lymphoma, Internal medicine, Genetic enhancement and Computational biology. His Antigen research integrates issues from Tumor necrosis factor alpha, Receptor, Chimeric Antigen Receptor T-Cell Therapy and Lymph node.

Between 2016 and 2021, his most popular works were:

  • Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas (679 citations)
  • A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma (528 citations)
  • Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. (443 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Immune system

His primary areas of investigation include Immunotherapy, Antigen, Chimeric antigen receptor, Cancer research and Cytokine release syndrome. His studies deal with areas such as Leukemia, Antibody and Monoclonal as well as Immunotherapy. His Antigen study frequently involves adjacent topics like T cell.

J. Joseph Melenhorst combines subjects such as Immune system, CD19, Lymphoma, Transforming growth factor and In vivo with his study of Cancer research. J. Joseph Melenhorst is investigating Cytokine release syndrome as part of his Immunology and Internal medicine and Cytokine release syndrome study. The concepts of his Immunology study are interwoven with issues in Toxicity and Epidermal growth factor receptor.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Chimeric antigen receptor T cells for sustained remissions in leukemia.

Shannon L. Maude;Noelle Frey;Pamela A. Shaw;Richard Aplenc.
The New England Journal of Medicine (2014)

3844 Citations

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

David L. Porter;Wei-Ting Hwang;Noelle V. Frey;Simon F. Lacey.
Science Translational Medicine (2015)

1162 Citations

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Stephen J. Schuster;Jakub Svoboda;Elise A. Chong;Sunita D. Nasta.
The New England Journal of Medicine (2017)

873 Citations

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

Elena Sotillo;David M. Barrett;Kathryn L. Black;Asen Bagashev.
Cancer Discovery (2015)

695 Citations

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Donald M. O’Rourke;MacLean P. Nasrallah;Arati Desai;Jan J. Melenhorst.
Science Translational Medicine (2017)

657 Citations

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia

David T. Teachey;David T. Teachey;Simon F. Lacey;Pamela A. Shaw;J. Joseph Melenhorst.
Cancer Discovery (2016)

559 Citations

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Joseph A. Fraietta;Simon F. Lacey;Elena J. Orlando;Iulian Pruteanu-Malinici.
Nature Medicine (2018)

509 Citations

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

Alfred L. Garfall;Marcela V. Maus;Wei-Ting Hwang;Simon F. Lacey.
The New England Journal of Medicine (2015)

506 Citations

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

Marco Ruella;David M. Barrett;Saad S. Kenderian;Olga Shestova.
Journal of Clinical Investigation (2016)

354 Citations

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

Elise A. Chong;J. Joseph Melenhorst;Simon F. Lacey;David E. Ambrose.
Blood (2017)

342 Citations

Best Scientists Citing J. Joseph Melenhorst

Carl H. June

Carl H. June

University of Pennsylvania

Publications: 103

Stephan A. Grupp

Stephan A. Grupp

Children's Hospital of Philadelphia

Publications: 79

Stanley R. Riddell

Stanley R. Riddell

Fred Hutchinson Cancer Research Center

Publications: 78

Marcela V. Maus

Marcela V. Maus

Massachusetts General Hospital

Publications: 69

David Price

David Price

University of Aberdeen

Publications: 66

Catherine M. Bollard

Catherine M. Bollard

George Washington University

Publications: 65

Renier J. Brentjens

Renier J. Brentjens

Memorial Sloan Kettering Cancer Center

Publications: 60

Cameron J. Turtle

Cameron J. Turtle

Fred Hutchinson Cancer Research Center

Publications: 60

Gianpietro Dotti

Gianpietro Dotti

University of North Carolina at Chapel Hill

Publications: 57

Helen E. Heslop

Helen E. Heslop

Baylor College of Medicine

Publications: 55

Malcolm K. Brenner

Malcolm K. Brenner

Baylor College of Medicine

Publications: 55

Crystal L. Mackall

Crystal L. Mackall

Stanford University

Publications: 54

David G. Maloney

David G. Maloney

Fred Hutchinson Cancer Research Center

Publications: 53

Michel Sadelain

Michel Sadelain

Memorial Sloan Kettering Cancer Center

Publications: 45

Hermann Einsele

Hermann Einsele

University of Würzburg

Publications: 43

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.